Type1Screen

Type1Screen offers Australian & New Zealand residents screening for the early detection of type 1 diabetes. Type1Screen is proudly supported by JDRF Australia.

This involves a blood test at your nearest pathology centre. Early detection can prevent serious illness & improve long term prognosis. Australian and New Zealand residents, who have a family member living with Type 1 Diabetes (T1D), are encouraged to find out more about Type1Screen. A simple blood test is all it takes to find out if you, or your child, at are increased risk of developing the condition. If you have a family history of T1D, when compared to the rest of the population, your risk of developing the condition is greater. Although there is currently no cure, early detection of T1D before symptoms present helps to prevent serious illness and provides options for intervention and prevention trials that may prevent or delay the onset of T1D.

26/11/2025

🚼 Can early oral daily insulin prevent ? New results from the POInT trial 🧬

Researchers screened 241,000+ newborns across Europe to find babies at high genetic risk for . Over 1,000 babies were enrolled and given either daily high-dose oral insulin or placebo from infancy to age 3 years.

🔍 What did they find?
The treatment was safe, but did not prevent the development of islet autoantibodies, the early markers of .

⚡ However, genetics mattered:
Infants with certain genes showed potential protection, while those with other genes did not benefit—and in some cases had increased risk. This suggests future prevention strategies may need to be targeted rather than one-size-fits-all.

💡 Why it matters:
POInT is one of the largest primary-prevention trials for type 1 diabetes ever conducted. While oral insulin alone didn’t prevent autoimmunity, the findings open the door to personalised prevention based on genetics.

🔬 Bottom line:
High-dose oral insulin is not the answer—but it offers another piece of the puzzle in understanding how type 1 diabetes might be prevented in the future.

Access the open access paper online at https://doi.org/10.1016/S0140-6736(25)01726-X

23/11/2025

An Australian video resource has been developed, by the ATIC community engagement panel, to assist with understanding type 1 diabetes development and potential immunotherapy interventions.

Immunotherapy for refers to treatments designed to modify or retrain the immune system to stop attacking the insulin-producing beta cells in the .

What makes this special?
✨ Designed for both the community AND healthcare professionals
✨ Comprehensive education about the stages of T1D the role of
✨ Created with community, for community

Watch the video online at: https://www.youtube.com/watch?v=Qjw57DuQgZ0

With an exciting trial launching in Australia early next year, now is the time to consider screening for the early markers. For more information, go to www,type1screen.org.

Supported by
Animation by Diabetes UK

💙

20/11/2025

Type 1 diabetes in your family?
Had some tests through an Australian screening study that show early markers?
Want to talk to someone about your experience?
Well want to hear from you!
Young people aged 9-18, and separately their caregivers, are sought for a one-off online interview about monitoring for .
Thinking about it? Scan the QR code, click on the link https://tinyurl.com/QuEST1D or email psychology post doc researcher mia.majstorovic@adelaide.edu.au to find out more.
Thanks!

17/11/2025

A and evaluated the efficacy of low-dose to prevent and treat exercise induced for people living with

Trials of low dose glucagon versus alternative therapies during controlled exercise were compared.

For individuals with , the study found low-dose glucagon reduces exercise-induced hypoglycaemia and time below range.

Making exercise more accessible for all individuals with will ultimately improve quality of life and help reduce diabetes-related complications.

Read more at: https://doi.org/10.2337/dc25-0702

13/11/2025

November 14th is International Diabetes Day 💙

Over 500 million people worldwide are living with diabetes. It is likely we all know someone living with diabetes! Whether it's Type 1, Type 2, Type3c, gestational, LADA, MODY or other types of diabetes, this condition affects real people—our colleagues, friends, and family members—every single day.

This International Diabetes Day, let's break the stigma and build understanding. The theme this year is "Diabetes at Work".

People with diabetes are managing their condition 24/7, making countless decisions about activity, medications, and even career choices that most of us never have to think about.

Here's at least 3 ways you can make a difference:
✅ Learn the early warning signs (the four Ts of T1D): excessive Thirst, frequent Toileting, unexplained Tiredness, getting Thinner
✅ Support, don't judge—diabetes management is complex and everyone's journey is different
✅ Get checked—early detection can improve long term outcomes, prevent serious complications, and may identify those eligible for clinical trials

Let's create a world where everyone with diabetes has the support, resources, and understanding they deserve.

💙

11/11/2025

November is Diabetes Awareness Month 💙
Did you know that 1.9 million Australians are living with ? Many of us know someone in our family, our workplace, or our footy team .
This year's theme is "Diabetes at Work" – because managing diabetes shouldn't mean missing out on career opportunities or feeling unsupported at your job.
Whether it's understanding when a colleague needs to check their blood glucose levels, ensuring access to medication storage, or simply creating a workplace culture where people feel safe to speak up about their health needs – we all have a role to play.
If you're living with diabetes, know your rights at work. If you're an employer or colleague, take time to learn how you can help create a supportive environment.
Let's work together to break down barriers and build workplaces where everyone can thrive.

08/11/2025

Hi! I am Arlo.

I am 7 years old and I am very .
This is me my after I had my finger pricked to do the Type1Screen test. It was a bit ouchy, but I didn't cry.
I found the blood drops interesting actually. Just 5 drops. And it was done.

My mum and dad helped me do this because my big brother has . He was only 1 when he was diagnosed 😢

For more information or to register someone with a family member living with go to www.type1screen.org

Thanks for supporting
💙

05/11/2025

🔬 Truly exciting news! Eli Lilly and Company is launching two major clinical trials for —a daily pill that could help preserve insulin production in people with the early markers for development, or recently diagnosed with .

Early studies led by members of our team in Australia, and funded by showed baricitinib helped people newly diagnosed with :
✅ Produce more insulin naturally
✅ Maintain blood glucose in target range
✅ Need less exogenous

The new trials will test whether baricitinib can:
1️⃣ Delay T1D onset in people found to have the early markers ( or early-stage T1D)
2️⃣ Preserve beta cells in people newly diagnosed (the cells that make insulin in the pancreas).

This drug is already approved for other conditions, and researchers are hopeful it could extend the "honeymoon period" when the pancreas can make its own insulin.

Might you or your family member be eligible? If you have ANY family history of , and thought about screening for , there has never been more motivation to do so. Check out our website for more information or to register for screening at www.type1screen.org

These trials will be open for recruitment globally soon, for those aged 1-35 years. Learn more via https://atic.svi.edu.au/clinical-trials/clinical-trials/ and spread the word!

ATIC Breakthrough T1D

02/11/2025

I'm sure you all know this nursery rhyme so feel free to sing along!

There were three in the bed and the little one said... Oh hang on a minute.... Not roll over... "I got screened!"

Yes, Dustin, Reagan and Aurora all snuggled up to support each other with the Type1Screen test for the early markers of (called ).

After being diagnosed 22 years ago this year, their mum, wanted to do everything to protect her kids from this condition. Hopefully no islet autoantibodies will be detected.

By detecting antibodies early, this gives families a chance to prevent (a life threatening condition with very high blood glucose levels), smooth the transition to therapy, and become eligible for available (check out the Australasian T1D Immunotherapy Collaborative).

For more information, or to register just like Dustin, Reagan and Aurora, go online to www.type1screen.org

31/10/2025

This trial provides the most convincing reason for screening family members for the early markers of ( ). For more information, or to register for screening, check out our website at www.type1screen.org

30/10/2025

Teplizumab is the first treatment proven to delay for those found to have early-stage . It is now FDA approved in America and under review for TGA approval in Australia.

However, researchers have discovered that helps some people with early more effectively than others! The difference may come down to how a person’s immune system works or is "tuned".

In this study by Sassi et al reported in the "Journal of Clinical Investigation", those people who responded well had more active immune cells (called T cells, NK/CD8⁺) that help control . In those who didn’t respond as well, other immune cells ( ) that drive inflammation were more dominant.

By analysing thousands of individual cells, the team identified a small group of 26 in the blood that can predict who is most likely to benefit from teplizumab, with high accuracy!

This research brings us a big step closer to personalised treatment and prevention for T1D. 🌟

To access Teplizumab, and other emerging therapies and to delay the need for therapy, individuals must be identified to be in early-stage before any symptoms develop. If you have a family history of , and want to determine your or your child's risk, check out our website www.type1screen.org for more information or to register.

Read more about the research in this open access article here: https://doi.org/10.1172/JCI176403

Address

Melbourne, VIC

Telephone

+61393427063

Website

http://www.type1screen.org/

Alerts

Be the first to know and let us send you an email when Type1Screen posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Want your practice to be the top-listed Clinic in Melbourne?